Roche Holding AG

ROG

CH0012032048

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 16:30:41 31/05/2024 BST			5-day change	1st Jan Change
231 ^CHF	+1.18%		+0.26%	-5.52%

09:03pm	Astra's Enhertu breast cancer trial shows 'unprecedented' results	RE
04:58pm	Astra's Enhertu delays breast cancer in patients with low HER2 levels	RE

U.K. Competition Watchdog Weighs Potential Impact of Roche-LumiraDx

May 20, 2024 at 07:38 am

By Mauro Orru

The U.K.'s Competition and Markets Authority is considering whether a deal for Roche Holding to buy certain companies linked to LumiraDx's point-of-care technology could stifle competition in the country.

The CMA said Monday that it is seeking comments from any interested party until June 3 to inform its views on the deal, though it hasn't yet launched a formal investigation into the transaction.

Roche and LumiraDx struck an agreement in December. The companies didn't respond to requests for comment.

Write to Mauro Orru at mauro.orru@wsj.com

(END) Dow Jones Newswires

05-20-24 0238ET

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	ROCHE HOLDING AG	231 CHF	+1.18%	+0.26%	206B
	LUMIRADX LIMITED	0.02 USD	-10.31%	-8.68%	7.18M

Latest news about Roche Holding AG

Astra's Enhertu breast cancer trial shows 'unprecedented' results	08:03pm	RE
Astra's Enhertu delays breast cancer in patients with low HER2 levels	03:58pm	RE
ROCHE HOLDINGS AG : Gets a Neutral rating from UBS	05-31	ZD
Transcript : Roche Holding AG - Shareholder/Analyst Call	05-31
ROCHE HOLDINGS AG : Goldman Sachs remains a Sell rating	05-30	ZD
Swiss Stocks Fall as Rate Jitters Intensify Amid Latest Inflation Data	05-29	MT
Global markets live: BHP, Anglo American, Lenovo, Nvidia, Apple...	05-29
European Midday Briefing : Mood Sours as Fed Rate-Cut Bets Curtailed	05-29	DJ
Roche: FDA grants priority review in breast cancer	05-29	CF
Roche's Metastatic Breast Cancer Treatment Granted Priority Review by US FDA	05-29	MT
Roche Breast-Cancer Drug Gets Priority Review in the U.S.	05-29	DJ
Roche Holding AG Announces U.S. Food and Drug Administration Accepted the New Drug Application and Granted Priority Review to Inavolisib, an Investigational, Oral Therapy, in Combination with Palbociclib (Ibrance®) and Fulvestrant	05-29	CI
Roche renews diagnostic partnership with Hitachi	05-27	CF
Roche appoints Director of Corporate Business Development	05-27	CF
Roche and Hitachi High-Tech Extend Their 46-Year Partnership, Paving the Way for Further Breakthroughs in Diagnostic Testing	05-27	CI
Roche Announces Management and Board Committee Changes	05-27	CI
Swiss Market Index Slumps as Economic Data Triggers Rate Jitters Anew	05-24	MT
ROCHE HOLDINGS AG : Gets a Neutral rating from Deutsche Bank	05-24	ZD
UK Watchdog Launches Probe into Roche's LumiraDx Purchase	05-24	MT
Roche, LumiraDx Deal Probed by U.K. Competition Watchdog	05-24	DJ
Transcript : Roche Holding AG - Analyst/Investor Day	05-22
Roche: FDA designation for blood test	05-22	CF
Roche Gets US FDA Breakthrough Designation For Lipoprotein(a) Test	05-22	MT
Roche Receives FDA Device Designation for Blood Test Measuring Lp(a)	05-22	CI
Europe stock pickers go old-school to ride the next wave in AI	05-22	RE

Chart Roche Holding AG

Duration

Period

More charts

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Sector

Pharmaceuticals

Calendar

05/06/2024 - Jefferies Global Healthcare Conference

Related indices

SMI , STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

ROCHE HOLDING : In line quarterly results won’t cut it for Roche

April 24, 2024 at 04:50 pm

Obesity: Roche joins the battle

December 04, 2023 at 03:48 pm

More Strategies

Ratings for Roche Holding AG

Trading Rating

Investor Rating

ESG Refinitiv

A+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

231 CHF

Average target price

277.5 CHF

Spread / Average Target

+20.14%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ROCHE HOLDING AG	-5.52%	206B
ELI LILLY AND COMPANY	+40.73%	739B
NOVO NORDISK A/S	+32.83%	598B
JOHNSON & JOHNSON	-6.30%	353B
MERCK & CO., INC.	+15.15%	318B
ABBVIE INC.	+4.05%	285B
ASTRAZENECA PLC	+15.00%	240B
NOVARTIS AG	+9.78%	210B
AMGEN INC.	+6.17%	164B
PFIZER, INC.	-0.45%	162B

Other Pharmaceuticals

Roche Holding AG

Equities

ROG

CH0012032048

Pharmaceuticals

U.K. Competition Watchdog Weighs Potential Impact of Roche-LumiraDx

Stocks mentioned in the article

EPS Revisions